http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2661572-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate | 2013-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_878d6e1a1d0c532d5a802cdec2919b88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b25a658f918930848e88e877d8b0b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d9b937630d31b1d401891b969daf8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00aa32dbcc5d99b4873617eb5598eb39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1904850377034b0d03f1e25333c30ee |
| publicationDate | 2018-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2661572-T3 |
| titleOfInvention | Immunoconjugates comprising anti-CD79b antibodies |
| abstract | An immunoconjugate having the formula Ab- (L-D) p, in which (a) Ab is the antibody; (b) L is a connector; (c) D is the cytotoxic agent; and (d) p varies from 1-8; wherein D has a structure selected from: ** Formula ** and Ab is an antibody that binds human CD79b, wherein the antibody comprises (a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23, (iv) HVR-L1 comprising a sequence of amino acids selected from SEQ ID NO: 18, 24 and 35, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25 and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26; or (b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25 and ( vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26; or c) a VH sequence that has at least 95% sequence identity with the amino acid sequence SEQ ID NO: 11; or d) a VL sequence that has at least 95% sequence identity with the amino acid sequence SEQ ID NO: 12; or e) a VH sequence as in (c) and a VL sequence as in (d); or f) a VH sequence having an amino acid sequence selected from SEQ ID NO: 9, 11 and 13; or g) a VL sequence having an amino acid sequence selected from SEQ ID NO: 8, 10, 12 and 14; or h) a VH sequence as in (f) and a VL sequence as in (g); or i) a VH sequence having the amino acid sequence of SEQ ID NO: 11; or j) a VL sequence having the amino acid sequence of SEQ ID NO: 12; or k) a VH sequence as in (i) and a VL sequence as in (j). |
| priorityDate | 2012-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 941.